SC 13G/A - Atlantic Coastal Acquisition Corp. II (0001893219) (Subject)

SC 13G/A - Atlantic Coastal Acquisition Corp. II (0001893219) (Subject)

SC 13D - Atlantic Coastal Acquisition Corp. II (0001893219) (Subject)

SC 13G/A - Atlantic Coastal Acquisition Corp. II (0001893219) (Subject)

SC 13G/A - Atlantic Coastal Acquisition Corp. II (0001893219) (Subject)

SC 13G - Atlantic Coastal Acquisition Corp. II (0001893219) (Subject)

SC 13G - Atlantic Coastal Acquisition Corp. II (0001893219) (Subject)

SC 13G - Atlantic Coastal Acquisition Corp. II (0001893219) (Subject)

NEW YORK, June 13, 2024 /PRNewswire/ -- Atlantic Coastal Acquisition Corp. II (NASDAQ:ACAB) (the "Company"), a special purpose acquisition company, announced that it had previously received written notification (the "Notice") from the Listing Qualifications Department of The Nasdaq Stock Market ("Nasdaq") on June 3, 2024 that, because the Company had not yet filed its Quarterly Report on Form 10-Q for the three month period ended March 31, 2024 (the "10-Q") with the Securities and Exchange Commission (the "SEC"), the Company was not in compliance with Nasdaq's continued listing requirements under Nasdaq Listing Rule 5250(c)(1). The Notice has no immediate effect on the listing of the Company

WOBURN, Mass. and NEW YORK, Jan. 22, 2024 (GLOBE NEWSWIRE) -- Abpro Corporation ("Abpro"), a biotech company with the mission of improving the lives of mankind facing severe and life-threatening diseases with next-generation antibody therapies, and Atlantic Coastal Acquisition Corp. II (NASDAQ:ACAB), a special purpose acquisition company ("Atlantic Coastal"), today announced the filing of a registration statement on Form S-4 (the "Registration Statement") with the U.S. Securities and Exchange Commission ("SEC") on January 19, 2024, which includes a preliminary proxy statement and prospectus in connection with its proposed business combination. Upon the closing of the proposed business

Abpro is a biotechnology company specializing in the development of next-generation antibody therapies intended to improve the lives of those with life-threatening diseases. The transaction values Abpro at $725 million and will help advance Abpro's drug pipeline to clinical trials. Abpro Corporation ("Abpro"), a biotechnology company with the mission of improving the lives of those facing severe and life-threatening diseases with next-generation antibody therapies, and Atlantic Coastal Acquisition Corp. II (NASDAQ:ACAB), a special purpose acquisition corporation ("Atlantic Costal"), today announced a term sheet to enter into a definitive business combination, which was entered into o

NEW YORK, Sept. 6, 2023 /PRNewswire/ -- Atlantic Coastal Acquisition Corp. (NASDAQ:ACAH) (the "Company"), a special purpose acquisition corporation, today announced that it filed a Schedule 14A Definitive Proxy Statement on September 6, 2023 (the "Definitive Proxy Statement") in connection with a special meeting (the "Special Meeting") to extend the amount of time the Company has to consummate a business combination (the "Extension"). This filing follows the Company's Schedule 14A Preliminary Proxy Statement that was filed on August 22, 2023 and the amendment thereto that was filed on September 5, 2023 (collectively, the "Preliminary Proxy Statement") in connection with the Special Meeting.

The Company Also Received a Notice of Non-compliance from Nasdaq for Failure to Timely File its Second Quarter 2023 Form 10-Q NEW YORK, Aug. 25, 2023 /PRNewswire/ -- Atlantic Coastal Acquisition Corp. (NASDAQ:ACAH) (the "Company"), a special purpose acquisition corporation, today announced that its Board of Directors approved to extend the date by which the Company would be required to consummate a business combination ("Extension"). This announcement follows a prior announcement on August 18, 2023 whereby the Company announced it would redeem its public shares. This Extension is subject to approval of the Company's shareholders at the Special Meeting that is currently scheduled for Septembe

NEW YORK, Aug. 18, 2023 /PRNewswire/ -- Atlantic Coastal Acquisition Corp. (NASDAQ:ACAH) (the "Company"), a special purpose acquisition corporation, today announced that it will redeem all of its outstanding shares of Class A common stock (the "public shares"), effective as of August 18, 2023, because the Company will not consummate an initial business combination within the time period required by its Second Amended and Restated Certificate of Incorporation (the "Certificate of Incorporation"). As stated in the Company's Certificate of Incorporation, if the Company is unable to complete an initial business combination by June 8, 2023 (subject to certain inapplicable exceptions), the Company

NEW YORK, May 30, 2023 /PRNewswire/ -- Atlantic Coastal Acquisition Corp. (NASDAQ:ACAH) (the "Company"), a special purpose acquisition corporation, announced that it had previously received written notification (the "Notice") from the Listing Qualifications Department of The Nasdaq Stock Market ("Nasdaq") on May 24, 2023 that, because the Company had not yet filed its Quarterly Report on Form 10-Q for the three month period ended March 31, 2023 (the "10-Q") with the Securities and Exchange Commission ("SEC"), the Company was not in compliance with Nasdaq's continued listing requirements under Nasdaq Listing Rule 5250(c)(1). The Notice has no immediate effect on the listing of the Company's s

NT 10-Q - Abpro Holdings, Inc. (0001893219) (Filer)

8-K - Abpro Holdings, Inc. (0001893219) (Filer)

25-NSE - Atlantic Coastal Acquisition Corp. II (0001893219) (Subject)

425 - Atlantic Coastal Acquisition Corp. II (0001893219) (Subject)

8-K - Atlantic Coastal Acquisition Corp. II (0001893219) (Filer)

425 - Atlantic Coastal Acquisition Corp. II (0001893219) (Subject)

8-K - Atlantic Coastal Acquisition Corp. II (0001893219) (Filer)

425 - Atlantic Coastal Acquisition Corp. II (0001893219) (Subject)

8-K - Atlantic Coastal Acquisition Corp. II (0001893219) (Filer)

425 - Atlantic Coastal Acquisition Corp. II (0001893219) (Subject)